Creating value in the lives of the people we serve, now and into the future UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge UCB share price More in UCB Shares Consensus by Visible Alpha Financial & Extra Financial performance Equity Story Download Center Corporate Governance Shareholders Financial Guidance The figures of the guidance 2026 as mentioned below were calculated on the same basis as the actual figures for 2025 and based on current rules and regulations. 2026 Revenue High single-digit % to low double-digit (in CER)Updated as per 26 February 2026Strong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®, with BIMZELX® access expansion & net pricing dynamics, Briviact LOE and a perimeter effect from sale of non-core assets in 2025CER = Constant Exchange Rate 2026 adj. EBITDA High single-digit % to High teens % (in CER)Updated as per 26 February 2026Adjusted for 2025 product sale & one-off items*: High teens % to high twenties % By continued investment behind 5 growth drivers, focused R&D execution and Evenity contribution*Excludes the benefit from a sale of established brands and one-off expenses CER = Constant Exchange Rate FX impactIf 31-Dec-25 FX rates would persist through 2026:~ -3 ppts on revenue growth~ -7 ppts on adjusted EBITDA growth Contact UCB IR Team investor-relations@ucb.com or a specific team member:Antje Witte, Head of Investor RelationsTel: +32 2 559 9414E-mail: Antje.Witte@ucb.com Yvonne Naughton, Head of Investor RelationsTel: +44 756 6790245E-mail: Yvonne.Naughton@ucb.com Sahar Yazdian, Investor Relations Lead Tel: +32 2 559 9137E-mail: Sahar.Yazdian@ucb.comDiyana Mishu, Investor Relations ManagerTel: +32 2 599 7446E-mail: Diyana.Mishu@ucb.com Book a virtual meeting Send us feedback UCB IR App
